Roxana Boanta
Research Subjects
Roxana Boanta has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Iulian Brezean
2 shared publications- Mihaela Misca2 shared publications
- Eduard Lucian Catrina
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
1 shared publication Mihaela Vilcu
1 shared publicationSorin Aldoescu
1 shared publicationSorin Petrea
1 shared publication
Latest Publications
- Open Access
- 17 May 2026
- Published by Elsevier in SSRN Electronic Journal
Intraoperative Indocyanine Green Angiography in Lower Rectal Cancer Surgery: Five-Year Experience of a Surgical Oncology Department
Introduction: Low and ultralow colorectal anastomoses, used in the surgical treatment of lower rectal cancer, are associated with an increased risk of anastomotic fistula and local complications, especially in the context of sphincter-sparing procedures. Near-infrared/ICG fluorescence technology enables objective assessment of tissue viability and can influence intraoperative decisions by modifying the transection level or adjusting the anastomotic configuration. Clinical data and the literature suggest a more pronounced potential benefit in anastomoses located at 4–8 cm from the anal margin, where vascular reserve is limited.Methods and Results: We conducted a prospective study at our service during 2021–2025, including patients in whom the ICG/NIR intraoperative technique was used, with a predilection for colorectal tumor pathology. In 2021–2025, our department surgically treated 420 patients with colorectal cancer, of whom 70 had rectal cancer, with 27 undergoing sphincter-sparing resections and the rest undergoing abdominoperineal amputation. Indocyanine green (ICG) was used in 22 cases to evaluate the viability of colonic segments and the perfusion of anastomoses, aiming to optimize reconstructive safety. Our department’s experience indicates an upward trend in restorative procedures, but this is accompanied by an increase in morbidity due to local complications, which necessitates integrating modern perfusion assessment methods, such as ICG, into treatment algorithms.Conclusions: Preservation of the anal sphincter remains an important goal for patients and a technical and oncologic challenge for the surgeon, requiring careful selection, rigorous counseling, and standardized intraoperative evaluation of perfusion. ICG/NIR technology can be a truly helpful instrument in the surgical decision-making process, influencing the surgical strategy and the postoperative evolution of patients.
- 17 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntraoperative Indocyanine Green Angiography in Lower Rectal Cancer Surgery: Five-Year Experience of a Surgical Oncology Department
Introduction: Low and ultralow colorectal anastomoses, used in the surgical treatment of lower rectal cancer, are associated with an increased risk of anastomotic fistula and local complications, especially in the context of sphincter-sparing procedures. Near-infrared/ICG fluorescence technology enables objective assessment of tissue viability and can influence intraoperative decisions by modifying the transection level or adjusting the anastomotic configuration. Clinical data and the literature suggest a more pronounced potential benefit in anastomoses located at 4–8 cm from the anal margin, where vascular reserve is limited.Methods and Results: We conducted a prospective study at our service during 2021–2025, including patients in whom the ICG/NIR intraoperative technique was used, with a predilection for colorectal tumor pathology. In 2021–2025, our department surgically treated 420 patients with colorectal cancer, of whom 70 had rectal cancer, with 27 undergoing sphincter-sparing resections and the rest undergoing abdominoperineal amputation. Indocyanine green (ICG) was used in 22 cases to evaluate the viability of colonic segments and the perfusion of anastomoses, aiming to optimize reconstructive safety. Our department’s experience indicates an upward trend in restorative procedures, but this is accompanied by an increase in morbidity due to local complications, which necessitates integrating modern perfusion assessment methods, such as ICG, into treatment algorithms.Conclusions: Preservation of the anal sphincter remains an important goal for patients and a technical and oncologic challenge for the surgeon, requiring careful selection, rigorous counseling, and standardized intraoperative evaluation of perfusion. ICG/NIR technology can be a truly helpful instrument in the surgical decision-making process, influencing the surgical strategy and the postoperative evolution of patients.
- Open Access
- 15 May 2026
- Published by Elsevier in SSRN Electronic Journal
Indocyanine Green Fluorescence-Guided In-Situ Parathyroid Preservation in Thyroid and Parathyroid Surgery: A Single-Centre Prospective Cohort Study
Background: Postoperative hypoparathyroidism remains the most frequent complication of thyroid surgery. Indocyanine green (ICG) fluorescence imaging assesses parathyroid perfusion intraoperatively, but most published series rely on liberal parathyroid autotransplantation. We assessed the feasibility, safety, and preliminary efficacy of ICG-guided in-situ parathyroid preservation under a strict no-autotransplantation policy. Methods: In this single-centre prospective cohort study at the Department of Endocrine Surgery, "C.I. Parhon" National Institute of Endocrinology (Bucharest, Romania), we enrolled in parallel two cohorts of 50 consecutive patients each between January and December 2024. The ICG cohort underwent intraoperative near-infrared fluorescence imaging with the Karl Storz IMAGE1 S™ Rubina® system; the control cohort was operated by the same surgical team during the same period when the imaging platform was not available. Allocation was determined by system availability and was effectively random with respect to clinical characteristics. Each parathyroid gland was scored on the Vidal Fortuny 0–1–2 scale. No autotransplantation was performed. The primary outcome was permanent hypoparathyroidism at 12 months, defined per the ESES/AAES/IAES 2025 consensus. Findings: Cohorts were matched for age, sex, BMI, and indication. Of 200 parathyroid glands scored, 123 (61·5%) scored 2 and 188 of 200 (94·0%) were identified. Permanent hypoparathyroidism occurred in 0 of 46 ICG patients versus 3 of 46 controls (6·5%; Fisher's exact p=0·24). The composite severe endpoint affected 2 of 46 (4·3%) ICG versus 8 of 46 (17·4%) controls (p=0·09). In the prespecified benign-disease subgroup, the composite severe endpoint occurred in 1 of 34 (2·9%) ICG versus 7 of 28 (25·0%) controls (Fisher's exact p=0·018). No ICG-related adverse events occurred. Interpretation: ICG fluorescence-guided in-situ parathyroid preservation without autotransplantation was feasible, safe, and signalled a reduction in severe hypoparathyroidism, particularly in benign thyroid disease. A randomised controlled trial is warranted.
- 15 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIndocyanine Green Fluorescence-Guided In-Situ Parathyroid Preservation in Thyroid and Parathyroid Surgery: A Single-Centre Prospective Cohort Study
Background: Postoperative hypoparathyroidism remains the most frequent complication of thyroid surgery. Indocyanine green (ICG) fluorescence imaging assesses parathyroid perfusion intraoperatively, but most published series rely on liberal parathyroid autotransplantation. We assessed the feasibility, safety, and preliminary efficacy of ICG-guided in-situ parathyroid preservation under a strict no-autotransplantation policy. Methods: In this single-centre prospective cohort study at the Department of Endocrine Surgery, "C.I. Parhon" National Institute of Endocrinology (Bucharest, Romania), we enrolled in parallel two cohorts of 50 consecutive patients each between January and December 2024. The ICG cohort underwent intraoperative near-infrared fluorescence imaging with the Karl Storz IMAGE1 S™ Rubina® system; the control cohort was operated by the same surgical team during the same period when the imaging platform was not available. Allocation was determined by system availability and was effectively random with respect to clinical characteristics. Each parathyroid gland was scored on the Vidal Fortuny 0–1–2 scale. No autotransplantation was performed. The primary outcome was permanent hypoparathyroidism at 12 months, defined per the ESES/AAES/IAES 2025 consensus. Findings: Cohorts were matched for age, sex, BMI, and indication. Of 200 parathyroid glands scored, 123 (61·5%) scored 2 and 188 of 200 (94·0%) were identified. Permanent hypoparathyroidism occurred in 0 of 46 ICG patients versus 3 of 46 controls (6·5%; Fisher's exact p=0·24). The composite severe endpoint affected 2 of 46 (4·3%) ICG versus 8 of 46 (17·4%) controls (p=0·09). In the prespecified benign-disease subgroup, the composite severe endpoint occurred in 1 of 34 (2·9%) ICG versus 7 of 28 (25·0%) controls (Fisher's exact p=0·018). No ICG-related adverse events occurred. Interpretation: ICG fluorescence-guided in-situ parathyroid preservation without autotransplantation was feasible, safe, and signalled a reduction in severe hypoparathyroidism, particularly in benign thyroid disease. A randomised controlled trial is warranted.